Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

American Journal of Medicine

Volumn 130, Issue 6, 2017, Pages S4-S17

  Thrasher, James ^a  

^a Medical Investigations Inc   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonist; Guidelines; Sodium glucose cotransporter 2 inhibitors; Treatment; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SODIUM GLUCOSE COTRANSPORTER 2;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MEDICATION THERAPY MANAGEMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85019983309     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.04.004     Document Type: Article

References (94)

1. Defronzo, R.A., Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
2. DeFronzo, R.A., Eldor, R., Abdul-Ghani, M., Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 36:Suppl 2 (2013), S127–S138.
3. Schwartz, S.S., Epstein, S., Corkey, B.E., Grant, S.F., Gavin, J.R. 3rd, Aguilar, R.B., The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care 39 (2016), 179–186.
4. Garber, A.J., Abrahamson, M.J., Barzilay, J.I., et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract 23 (2017), 207–238.
5. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
6. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 40:Suppl 1 (2017), S64–S74.
7. American Diabetes Association. 6. Glycemic targets. Diabetes Care 40:Suppl 1 (2017), S48–S56.
8. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
9. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
10. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
11. Zinman, B., Lachin, J.M., Inzucchi, S.E., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 374, 2016, 1094.
12. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
13. Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
14. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
15. Gong, L., Goswami, S., Giacomini, K.M., Altman, R.B., Klein, T.E., Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22 (2012), 820–827.
16. An, H., He, L., Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol 228 (2016), R97–R106.
17. Lüscher, T., Paneni, F., Cardioprotection in the T2DM patient. Am J Med 130 (2017), S18–S29.
18. Hirst, J.A., Farmer, A.J., Ali, R., Roberts, N.W., Stevens, R.J., Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 35 (2012), 446–454.
19. Rojas, L.B., Gomes, M.B., Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr, 5, 2013, 6.
20. Zonszein, J., Groop, P.H., Strategies for diabetes management: using newer oral combination therapies early in the disease. Diabetes Ther 7 (2016), 621–639.
21. US Food and Drug Administration. Drug Safety Communication (April 8, 2016): FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf. Accessed April 18, 2016.
22. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
23. Madsbad, S., Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18 (2016), 317–332.
24. Tahrani, A.A., Barnett, A.H., Bailey, C.J., Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12 (2016), 566–592.
25. Blevins, T., Pullman, J., Malloy, J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96 (2011), 1301–1310.
26. Drucker, D.J., Buse, J.B., Taylor, K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 (2008), 1240–1250.
27. Ji, L., Onishi, Y., Ahn, C.W., et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig 4 (2013), 53–61.
28. Buse, J.B., Nauck, M., Forst, T., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
29. Buse, J.B., Rosenstock, J., Sesti, G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009), 39–47.
30. Rosenstock, J., Raccah, D., Koranyi, L., et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36 (2013), 2945–2951.
31. Pratley, R.E., Nauck, M.A., Barnett, A.H., et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2 (2014), 289–297.
32. Dungan, K.M., Povedano, S.T., Forst, T., et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 (2014), 1349–1357.
33. Aroda, V.R., Henry, R.R., Han, J., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 34 (2012), 1247–1258.e1222.
34. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
35. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
36. ® (exenatide extended-release), for injectable suspension. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s015s016s017s018lbl.pdf Accessed March 23, 2017.
37. TM (dulaglutide) injection, for subcutaneous use. Available at: http://pi.lilly.com/us/trulicity-uspi.pdf Accessed March 22, 2017.
38. ® (albiglutide) injection, for subcutaneous use. Available at: https://www.gsksource.com/gskprm/htdocs/documents/TANZEUM-PI-MG-IFU-COMBINED.PDF Accessed March 23, 2017.
39. ® (exenatide) injection. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021773s040lbl.pdf Accessed March 23, 2017.
40. ® (liraglutide [rDNA origin]) injection, for subcutaneous use. Available at: http://www.novo-pi.com/victoza.pdf Accessed March 23, 2017.
41. ® (lixisenatide) injection, for subcutaneous use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf Accessed March 23, 2017.
42. Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., et al. American Association of Clinical Endocrinologists and American College of Endocrinology–clinical practice guidelines for developing a diabetes mellitus comprehensive care plan–2015. Endocr Pract 21:Suppl 1 (2015), 1–87.
43. Abdul-Ghani, M.A., DeFronzo, R.A., Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14 (2008), 782–790.
44. Abdul-Ghani, M.A., DeFronzo, R.A., Norton, L., Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62 (2013), 3324–3328.
45. ® (empagliflozin and linagliptin), tablets, for oral use. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Glyxambi/Glyxambi.pdf Accessed March 23 2017.
46. ® (dapagliflozin and saxagliptin) tablets, for oral use. Available at: http://www.azpicentral.com/qtern/qtern.pdf#page=1 Accessed March 1, 2017.
47. Storgaard, H., Gluud, L.L., Bennett, C., et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One, 11, 2016, e0166125.
48. ® trial. Eur Heart J 37 (2016), 1526–1534.
49. ® (empagliflozin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf Accessed December 9, 2016.
50. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Optimising the analysis strategy for the CANVAS Program - a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials [e-pub ahead of print]. Diabetes Obes Metab, 2017, 10.1111/dom.12924 Accessed March 31, 2017.
51. DECLARE-TIMI 58. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI 58). Available at: https://clinicaltrials.gov/ct2/show/NCT01730534 Accessed September 8, 2016.
52. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
53. ®: the nephrologist's point of view. Am J Med 130 (2017), S63–S72.
54. ® (canagliflozin) tablets, for oral use. Available at: https://www.invokanahcp.com/sites/www.invokanahcp.com/files/prescribing-information-invokana.pdf Accessed March 22, 2017.
55. ® (dapagliflozin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s011lbl.pdf Accessed March 22, 2017.
56. Scheen, A.J., SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 14 (2015), 1879–1904.
57. US Food and Drug Administration. Drug Safety Communication (December 4, 2015): FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf Accessed November 29, 2016.
58. US Food and Drug Administration. Drug Safety Communication (June 14, 2016): FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf Accessed November 29, 2016.
59. US Food and Drug Administration. Drug Safety Communication (May 15, 2015): FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf Accessed November 29, 2016.
60. Handelsman, Y., Henry, R.R., Bloomgarden, Z.T., et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22 (2016), 753–762.
61. Kohler, S., Salsali, A., Hantel, S., et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther 38 (2016), 1299–1313.
62. Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
63. ® (alogliptin and pioglitazone), tablets for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022426s009lbl.pdf Accessed March 23, 2017.
64. Zhang, X., Zhao, Q., Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis. J Hypertens 34 (2016), 167–175.
65. Scheen, A.J., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
66. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
67. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
68. White, W.B., Pratley, R., Fleck, P., et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 15 (2013), 668–673.
69. Lehrke, N., Marx, N., Diabetes mellitus and heart failure. Am J Med 130 (2017), S40–S50.
70. ® (saxagliptin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022350s014lbl.pdf Accessed November 29, 2016.
71. ® (linagliptin) tablets. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201280s015lbl.pdf Accessed January 12, 2017.
72. ® (sitagliptin) tablets. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s034lbl.pdf Accessed November 8, 2016.
73. ® (alogliptin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf Accessed January 11, 2017.
74. Egan, A.G., Blind, E., Dunder, K., et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med 370 (2014), 794–797.
75. Monsalve, F.A., Pyarasani, R.D., Delgado-Lopez, F., Moore-Carrasco, R., Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm, 2013, 2013, 549627.
76. Fuchtenbusch, M., Standl, E., Schatz, H., Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108 (2000), 151–163.
77. Takeda Pharmaceuticals America Inc. Prescribing information (12/2016): ACTOS (pioglitazone) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021073s048lbl.pdf Accessed January 11, 2017.
78. ® (rosiglitazone maleate) tablets. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021071s051lbl.pdf Accessed December 23, 2016.
79. Wilcox, R., Bousser, M.G., Betteridge, D.J., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007), 865–873.
80. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
81. Mitka, M., FDA eases restrictions on the glucose-lowering drug rosiglitazone. JAMA, 310, 2013, 2604.
82. Seino, S., Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 55 (2012), 2096–2108.
83. Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J.E., Gerstein, H.C., The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 33 (2010), 1859–1864.
84. Gaziano, J.M., Cincotta, A.H., O'Connor, C.M., et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33 (2010), 1503–1508.
85. Gaziano, J.M., Cincotta, A.H., Vinik, A., Blonde, L., Bohannon, N., Scranton, R., Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc, 1, 2012, e002279.
86. Beverly, E.A., Hultgren, B.A., Brooks, K.M., Ritholz, M.D., Abrahamson, M.J., Weinger, K., Understanding physicians' challenges when treating type 2 diabetic patients' social and emotional difficulties: a qualitative study. Diabetes Care 34 (2011), 1086–1088.
87. Derr, R.L., Sivanandy, M.S., Bronich-Hall, L., Rodriguez, A., Insulin-related knowledge among health care professionals in internal medicine. Diabetes Spectrum 20 (2007), 177–185.
88. Peyrot, M., Rubin, R.R., Lauritzen, T., Snoek, F.J., Matthews, D.R., Skovlund, S.E., Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 22 (2005), 1379–1385.
89. Khunti, K., Wolden, M.L., Thorsted, B.L., Andersen, M., Davies, M.J., Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36 (2013), 3411–3417.
90. Sanofi-Aventis US LLC. Prescribing information (11/2016): SOLIQUA™ 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208673s000lbl.pdf Accessed January 11, 2017.
91. ® 100/3.6 (insulin degludec and liraglutide injection), for subcutaneous use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208583s000lbl.pdf Accessed December 12, 2016.
92. American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care 39:Suppl 1 (2016), S52–S59.
93. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 40 (2016), 484–486.
94. Torio C, Moore B. National inpatient hospital costs: the most expensive conditions by payer, 2013. HCUP Statistical Brief #204. May 2016. Agency for Healthcare Research and Quality, Rockville, MD. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.jsp. Accessed October 21, 2016.